| Compound | Ipamorelin + Tesamorelin |
|---|---|
| Category | Vendor blend (GH secretagogues) |
| Class | Growth Hormone and Growth Factors |
| Evidence tier | Minimal evidence |
| WADA status | Prohibited in sport (or falls under a prohibited class) — see the WADA reference table |
| Sold on this site | No — this is a reference database |
Overview
Ipamorelin + Tesamorelin — a vendor blend (gh secretagogues) — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A vendor combination pairing a ghrelin-receptor agonist with the approved GHRH analog tesamorelin. The combination has not been studied in any published trial.
Mechanism of Action
The stacking rationale is the same dual-lever GH stimulation logic as other GHRH/GHRP blends.
Research and Evidence
No combination evidence exists; tesamorelin’s evidence applies only to its approved monotherapy indication.
Safety and Side Effects
Unknown; combining an approved drug with an unapproved secretagogue outside medical supervision compounds both uncertainties. Prohibited in sport.
Frequently Asked Questions
What is the evidence tier of Ipamorelin + Tesamorelin?
Ipamorelin + Tesamorelin is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Ipamorelin + Tesamorelin an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Ipamorelin + Tesamorelin?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.